AR005221A1 - Uso de heparina de ultra bajo peso molecular y composiciones que los comprende para tratar las reacciones alérgicas y enfermedades inflamatorias fase posterior - Google Patents

Uso de heparina de ultra bajo peso molecular y composiciones que los comprende para tratar las reacciones alérgicas y enfermedades inflamatorias fase posterior

Info

Publication number
AR005221A1
AR005221A1 ARP980103829A ARP980103829A AR005221A1 AR 005221 A1 AR005221 A1 AR 005221A1 AR P980103829 A ARP980103829 A AR P980103829A AR P980103829 A ARP980103829 A AR P980103829A AR 005221 A1 AR005221 A1 AR 005221A1
Authority
AR
Argentina
Prior art keywords
molecular weight
low molecular
allergic reactions
allergic
inflammatory diseases
Prior art date
Application number
ARP980103829A
Other languages
English (en)
Original Assignee
Ivax Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc filed Critical Ivax Research Inc
Publication of AR005221A1 publication Critical patent/AR005221A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Un método para tratar un paciente mamífero que sufre o es propenso a una condición que comprende reacciones alérgicas de fase posterior, hiperrespuestade vía respiratoria o reacciones inflamatorias, por ejemplo, asma, rinitis alérgica, dermatitis alérgica, conjuntivitis alérgica, enfermedadinflamatoria de intestino o artritis reumatoidea, que comprende la administración del paciente de una composición farmacéutica oral, parenteral,intrabonquial, local, intranasal o intraocular que contiene en cada dosis desde aproximadamente 0,005 hasta aproximadamenate 1,0 mg por kilogramo depeso de cuerpo de paciente de heparinas de peso molecular ultra bajo (ULMWH) u otro polisacárido sulfatado que posea pesos moleculares promedio deaproximadamente 1.000 - 3.000 daltons. Se describen también composiciones inhalantes convenientes y otras composiciones farmacéuticas para uso en elmétodo de tratamiento novedoso.
ARP980103829A 1997-08-04 1998-08-03 Uso de heparina de ultra bajo peso molecular y composiciones que los comprende para tratar las reacciones alérgicas y enfermedades inflamatorias fase posterior AR005221A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/904,565 US5980865A (en) 1995-08-18 1997-08-04 Method for treating late phase allergic reactions and inflammatory diseases

Publications (1)

Publication Number Publication Date
AR005221A1 true AR005221A1 (es) 1999-04-28

Family

ID=25419368

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103829A AR005221A1 (es) 1997-08-04 1998-08-03 Uso de heparina de ultra bajo peso molecular y composiciones que los comprende para tratar las reacciones alérgicas y enfermedades inflamatorias fase posterior

Country Status (26)

Country Link
US (2) US5980865A (es)
EP (1) EP1003479B1 (es)
JP (1) JP2001511439A (es)
KR (1) KR100551773B1 (es)
CN (1) CN1092049C (es)
AR (1) AR005221A1 (es)
AT (1) ATE323500T1 (es)
AU (1) AU8684698A (es)
BR (1) BR9811823A (es)
CA (1) CA2298445C (es)
DE (1) DE69834256T2 (es)
DK (1) DK1003479T3 (es)
ES (1) ES2260843T3 (es)
HK (1) HK1030370A1 (es)
HU (1) HUP0003013A3 (es)
IL (1) IL134230A0 (es)
NO (1) NO20000558L (es)
NZ (1) NZ502498A (es)
PL (1) PL191796B1 (es)
PT (1) PT1003479E (es)
RU (1) RU2209624C2 (es)
SK (1) SK1172000A3 (es)
TW (1) TW585771B (es)
UA (1) UA75022C2 (es)
WO (1) WO1999006025A1 (es)
ZA (1) ZA986890B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799766B2 (en) * 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US7906153B2 (en) * 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US20050220909A1 (en) * 2004-03-30 2005-10-06 Theoharides Theoharis C Composition for protection against superficial vasodilator flush syndrome
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US6984667B2 (en) * 1998-04-08 2006-01-10 Theta Biomedical Consulting And Development Co. Synergistic proteoglycan compositions for inflammatory conditions
US20080153761A1 (en) * 1998-04-08 2008-06-26 Theoharides Theoharis C Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
GB9917092D0 (en) 1999-07-22 1999-09-22 Ml Lab Plc Treatment of angiogenesis-dependent conditions
US20040230559A1 (en) * 1999-08-09 2004-11-18 Mark Newman Information processing device and information processing method
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
GB0003048D0 (en) * 2000-02-11 2000-03-29 Dealler Stephen F The therapeutic use of polysulphonated polyglycosides or other polyanionic compounds in autism
SE0001631D0 (sv) * 2000-05-04 2000-05-04 Sahltech Ab New use
WO2001093846A2 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
DK1511466T4 (en) 2002-02-18 2015-03-30 Ockham Biotech Ltd Use of glycosaminoglycans, such as, for example, heparin, for the treatment of respiratory disorders such as COPD
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
EP1539192A1 (en) * 2002-04-24 2005-06-15 Medicarb AB Composition and kit for the treatment of inflammatory bowel diseases
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
WO2004084918A1 (ja) * 2003-03-25 2004-10-07 Sekisui Chemical Co., Ltd. 皮膚止痒外用組成物
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
US7923043B2 (en) * 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
CN101010305B (zh) 2004-08-20 2010-08-11 曼金德公司 二酮哌嗪合成的催化反应
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
CA2579884C (en) * 2004-09-10 2013-12-31 Pharmaorigin Aps Methods for treating local tracheal, bronchial or alveolar bleeding or hemoptysis
TW200621794A (en) * 2004-10-06 2006-07-01 Akzo Nobel Nv Pulmonary administration of an antithrombotic compound
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
MX358592B (es) 2005-09-14 2018-08-27 Mannkind Corp Método para formulación de fármaco basado en el aumento de la afinidad de superficies de micropartículas cristalinas hacia agentes activos.
US8057840B2 (en) * 2006-01-25 2011-11-15 Tate & Lyle Ingredients Americas Llc Food products comprising a slowly digestible or digestion resistant carbohydrate composition
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
CN101095693B (zh) * 2006-06-29 2010-10-13 重庆华邦制药股份有限公司 治疗皮炎的复方药物
WO2008144836A1 (en) * 2007-05-31 2008-12-04 Glycan Biosciences Sulphated xylans for treatment or prophylaxis of respiratory diseases
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
KR101548092B1 (ko) 2008-06-13 2015-08-27 맨카인드 코포레이션 건조 분말 흡입기 및 약물 투여 시스템
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9176146B2 (en) * 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9050275B2 (en) * 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
MX2012006265A (es) * 2009-12-03 2012-07-25 Opko Health Inc Formulaciones disacaridas hipersulfatadas.
US20110212181A1 (en) * 2010-02-26 2011-09-01 The University Of Hong Kong Compositions and methods for treating chronic respiratory inflammation
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
WO2012058424A1 (en) * 2010-10-29 2012-05-03 Opko Health, Inc. Hypersulfated disaccharides to treat elastase related disorders
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
EP2706990A1 (en) * 2011-05-12 2014-03-19 Aventis Pharma S.A. Semuloparin for the prevention of venous thromboembolism in cancer patients receiving chemotherapy
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
JP6018640B2 (ja) 2011-10-24 2016-11-02 マンカインド コーポレイション 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2797650T3 (es) 2011-12-07 2020-12-03 Allergan Inc Administración de lípido eficiente a película lagrimal humana usando un sistema de emulsión sensible a sal
RU2650035C2 (ru) 2012-07-12 2018-04-06 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
EP3191091B1 (en) 2014-09-12 2020-08-26 Children's Medical Center Corporation Dietary emulsion formulations and methods for using the same
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MX2017006474A (es) 2014-11-25 2017-09-12 Allergan Inc Composiciones oftalmicas estabilizadas de omega 3.
WO2018035050A1 (en) 2016-08-16 2018-02-22 Opko Pharmaceuticals, Llc Pure heptasulfated disaccharides having improved oral bioavailability
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
US11718609B2 (en) 2016-12-13 2023-08-08 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CN114053251A (zh) * 2020-07-29 2022-02-18 苏州融析生物科技有限公司 硫酸化多糖吸入制剂及其在防治新冠病毒相关疾病中的应用
US20220211746A1 (en) * 2021-01-07 2022-07-07 Bionovax Corp. Special heparinoid composition, with repair, prophylactic and anti-inflammatory effects, applied to the lungs

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3405120A (en) * 1966-01-27 1968-10-08 Green Cross Corp Low molecular chondroitin sulfate and method for manufacturing the same
IT1195497B (it) 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
FR2584728B1 (fr) * 1985-07-12 1987-11-20 Choay Sa Procede de sulfatation de glycosaminoglycanes et de leurs fragments
FR2584606A1 (fr) * 1985-07-12 1987-01-16 Dropic Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif
IT1230582B (it) * 1988-10-21 1991-10-28 Opocrin S P A Lab Farmabiologi Oliogosaccaridi di dermatan solfato ed eparina aventi attivita' antiaterosclerotica
US5380716A (en) 1988-12-15 1995-01-10 Glycomed, Inc. Sulfated polysaccharides as inhibitors of smooth muscle cell proliferation
US5032679A (en) 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
KR100235782B1 (ko) * 1991-05-02 1999-12-15 파울리나 벤-아미 병리학적 과정의 예방 또는 치료를 위한 성분물
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
FR2704861B1 (fr) * 1993-05-07 1995-07-28 Sanofi Elf Fractions d'héparine purifiées, procédé d'obtention et compositions pharmaceutiques les contenant.
US5527785A (en) * 1993-05-14 1996-06-18 The Regents Of The University Of California Selectin receptor modulating compositions
SE9303612D0 (sv) * 1993-11-02 1993-11-02 Kabi Pharmacia Ab New use
US5690910A (en) * 1995-08-18 1997-11-25 Baker Norton Pharmaceuticals, Inc. Method for treating asthma

Also Published As

Publication number Publication date
US6193957B1 (en) 2001-02-27
NO20000558D0 (no) 2000-02-03
PL191796B1 (pl) 2006-07-31
BR9811823A (pt) 2000-08-15
EP1003479B1 (en) 2006-04-19
WO1999006025A1 (en) 1999-02-11
NZ502498A (en) 2002-05-31
DE69834256T2 (de) 2007-02-01
IL134230A0 (en) 2001-04-30
HK1030370A1 (en) 2001-05-04
HUP0003013A3 (en) 2001-11-28
TW585771B (en) 2004-05-01
KR20010022533A (ko) 2001-03-15
ATE323500T1 (de) 2006-05-15
AU8684698A (en) 1999-02-22
ZA986890B (en) 1999-01-28
CN1269715A (zh) 2000-10-11
SK1172000A3 (en) 2001-03-12
JP2001511439A (ja) 2001-08-14
DE69834256D1 (de) 2006-05-24
CA2298445C (en) 2007-07-17
EP1003479A4 (en) 2001-01-17
US5980865A (en) 1999-11-09
CA2298445A1 (en) 1999-02-11
PT1003479E (pt) 2006-08-31
CN1092049C (zh) 2002-10-09
UA75022C2 (en) 2006-03-15
ES2260843T3 (es) 2006-11-01
PL338551A1 (en) 2000-11-06
NO20000558L (no) 2000-03-14
EP1003479A1 (en) 2000-05-31
HUP0003013A2 (hu) 2001-01-29
DK1003479T3 (da) 2006-07-31
RU2209624C2 (ru) 2003-08-10
KR100551773B1 (ko) 2006-02-13

Similar Documents

Publication Publication Date Title
AR005221A1 (es) Uso de heparina de ultra bajo peso molecular y composiciones que los comprende para tratar las reacciones alérgicas y enfermedades inflamatorias fase posterior
Palmoski et al. Effect of salicylate on proteoglycan metabolism in normal canine articular cartilage in vitro
ATE26281T1 (de) Depolymerisiertes und supersulfatiertes heparin, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
ES2545525T3 (es) Polímeros biocompatibles, composiciones que los contienen y su uso para la preparación de medicamentos
US7863256B2 (en) Amide derivatives of hyaluronic acid in osteoarthrosis
US20070054878A1 (en) Use of hyaluronic acid derivatives for inhibiting inflammatory arthritis
NO315840B1 (no) Anvendelse av distrontiumsaltet av 2-[N,N- di(karboksymetyl)amino]-3-cyano-4-karboksymetyltiofen-5-karboksylsyre til fremstilling av etfarmasöytisk preparat for behandling av artrose
KR20090014359A (ko) 퇴행성 골관절염을 치료하기 위한 황산화 히알루론산
CN102803297A (zh) 糖胺聚糖类(gag)与生物活性分子的缀合物的合成方法、聚合缀合物及其相关用途
KR100728096B1 (ko) 관절성 질환 치료제
Hao et al. Local injection of bone mesenchymal stem cells and fibrin glue promotes the repair of bone atrophic nonunion in vivo
BR9808008A (pt) Processo para o tratamento anticoagulante e/ou antitrombótico de um ser humano ou outro paciente animal de sangue quente, usos de um oligossacarìdeo sulfatado e na fabricação de um medicamento, e, composição farmacêutica ou veterinária para tratamento anticoagulante e/ou antitrombótico.
Capanna et al. Temporary resection-arthrodesis of the knee using an intramedullary rod and bone cement
EP1917018B1 (en) Inulin sulphate for the treatment of osteoarthritis
ES2281265B1 (es) Composiciones para el tratamiento de la artrosis.
US20050075314A1 (en) Use of sulfated glycosaminoglycans for establishing effective labor in women
CN111163808A (zh) 含有透明质酸和肌肽的药物组合物及其相关用途
Dahl Biosynthesis of proteoglycans and hyaluronate in rabbit corneal fibroblast cultures. Variation with age of the cell line and effect of foetal calf serum
US3567835A (en) Mucolytic salts,compositions and process for treating mucus
AR006214A1 (es) Un metodo para movilizar celulas mediante el tratamiento con hialuronan (ha)
EP2155208B1 (en) Disaccharides for the treatment of tendons and ligaments
JP4960568B2 (ja) 変形性関節症の処置のためのポリ硫酸化シクロデキストリンの使用
CN107840897A (zh) 一种用于治疗骨关节炎的透明质酸镁盐及其制备方法和应用
Clegg Christopher G. Jackson
ScoTr et al. SOUTH-EAST ASIA AND PACIFICAREA LEAGUE AGAINST RHEUMATISM

Legal Events

Date Code Title Description
FA Abandonment or withdrawal